Introduction
MM is a B cell neoplasm associated with clonal proliferation of malignant plasma cells. It is characterized by infiltration of BM with tumor cells, cortical and medullary bone destruction, and suppression of hematopoiesis. In the year 2001, MM will be diagnosed in 13 700 patients in the United States and account for 20% deaths from hematological malignancies. in the majority of cases despite advances in high-dose chemotherapy and transplantation. We 2 and others 3, 4 have demonstrated that IL-6 is a major growth and survival factor for MM cells. IL-6 is secreted by BMSCs and some MM cells and is markedly upregulated by adhesion of MM cells to BMSCs. 5 IL-6 mediates both MM cell proliferation 6 and inhibits Fas and dexamethasone induced apoptosis. 7 The observation that IL-6 levels are usually high in patients with active MM, 8 coupled with the decrease in MM cells after administration of anti-IL-6 monoclonal antibodies, 9 suggests its in vivo significance. Thus IL-6 appears to be an important cytokine involved in the maintenance and progression of MM. 10 Many malignant neoplasms are dependent on neovascularization to sustain growth. 11 Various studies have demonstrated that the number and density of microvessels in solid tumors including breast, 12 prostate 13 and non small cell lung cancers, 14 as well as neuroblastomas, 15 directly correlates with growth, invasion, and dissemination. Increased angiogenesis often predicts poor prognosis. Angiogenic cytokines such as bFGF and VEGF are important mediators of angiogenesis. 16 Overexpression of VEGF is associated with increased angiogenesis, growth, and metastasis in solid tumors. Various human cancers, including lung, 17 gastrointestinal 18 and prostate 19 cancers, secrete VEGF, and in solid cancers, VEGF mRNA and protein expression has been correlated with advancing disease. 17 Elevated levels of bFGF have been reported in serum 20 and urine 21 of patients with cancer. Although the importance of angiogenesis in solid tumors is well known, its role in growth and survival of hematological malignancies has only recently been realized. Ribatti et al 22 reported an increase in microvessel density in lymph nodes in B cell non-Hodgkin's lymphoma (NHL), which correlated with the severity of disease. 22 Fielder et al 23 reported transcription of VEGF in a high proportion of patients with acute myeloid leukemia (AML). Increased angiogenesis and higher levels of VEGF, bFGF, and hepatocyte growth factor (HGF) have been reported in AML, chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS). 24 In contrast, low intracellular VEGF protein in AML cells correlated with higher complete response rates and longer survival. 25 In MM, increased angiogenesis [26] [27] [28] and elevated mast cell density 26 is highly correlated with plasma cell labelling index (LI). 26, 27 This increased angiogenesis persists even after achievement of complete response following stem cell transplantation, suggesting the utility of combined chemotherapeutic and antiangiogenic drug regimens. 29 Elevated serum levels of angiogenic cytokines such as VEGF, bFGF, and HGF have been reported both in patients with MM 30 and polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome. 31 Recently, a remarkable anti-tumor effect of thalidomide has been noted by multiple groups in patients with refractory and relapsed MM. [32] [33] [34] [35] [36] [37] Although this marked anti-tumor activity of thalidomide is attributed to its anti-angiogenic properties, 38 its ability to modulate cytokines, alter adhesion molecule expression, and enhance host cell anti-tumor immunity may also mediate anti-MM activity. 39 In the present study, we characterized the regulation of angiogenic cytokines (VEGF and bFGF) and IL-6 secretion in the BM millieu. Importantly we demonstrate that both VEGF and IL-6 secretion are upregulated by MM to BMSC binding, and that thalidomide and its analog, IMiD1 (CC4047), abrogate this response.
Materials and methods

Reagents Cytokines and antibodies:
Recombinant human IL-6, recombinant human VEGF 165 , neutralizing anti-human IL-6 monoclonal antibody (MoAb), and neutralizing goat antihuman VEGF polyclonal antibody were purchased from R&D Systems (Minneapolis, MN, USA). These reagents were reconstituted with sterile PBS and stored at 4°C. Recombinant IL-6 was used at 10 ng/ml (ED 50 on an IL-6 dependent plasmacytoma cell line = 0.2-0.8 ng/ml) and recombinant VEGF 165 at 100 ng/ml (ED 50 on HUVEC cells = 2-6 ng/ml). Anti-human IL-6 MoAb was used at 10 g/ml (ND 50 on an IL-6 dependent plasmacytoma cell line in the presence of 2.5 ng/ml of rhIL-6 = 0.05-0.15 g/ml). Goat anti-human VEGF 165 polyclonal antibody was used at 1 g/ml (ND 50 on VEGF-dependent human umbilical vein endothelial cells (HUVEC) in the presence of 10 ng/ml of rhVEGF = 0.01-0.03 g/ml).
Thalidomide and its analog IMiD 1:
Thalidomide and its potent analog immunomodulatory drug (IMiD1-CC4047) (Celgene Corporation, Warren, NJ, USA) were dissolved in dimethyl sulfoxide (DMSO) (Sigma, St Louis, MO, USA) and stored at −20°C. These drugs were diluted in culture medium (0.0001 to 100 M) immediately before use. The thalidomide analog (IMiD1-CC4047) stimulates T cell proliferation, as well as interleukin-2 and interferon-␥ secretion, and is not a phosphodiesterase 4 inhibitor. This drug also inhibits tumor necrosis factor-␣, interleukin-1␤ and IL-6 secretion, but greatly increases interleukin-10 production by lipopolysaccharide-stimulated peripheral blood mononuclear cells (PBMCs). 40 Thalidomide and its analog-IMiD 1 (CC4047) were used at a final concentration of 100 M and 1 M, respectively. 
Human MM cells
BMSCs
BM specimens were obtained from patients with MM and from normal healthy donors. PBMCs were separated by Ficoll-Hypaque density sedimentation and were used to establish long-term BM cultures according to the method described by Gartner and Kaplan, with slight modifications. 41 PBMCs were suspended in 8 ml growth medium containing Iscove's modified Dulbecco's medium (IMDM) (Sigma), 20% FBS, Pen (100 U/ml), Strep (100 g/ml), and 8 mM L-glutamine. The nonadherent cells were removed after 2 days, and thereafter the media was changed once or twice weekly. In some cultures, human recombinant ␤-epidermal growth factor (4 ng/ml) was added every 3-4 days to augment the growth of BMSCs. When an adherent monolayer had developed, the cells were harvested in Hank's buffered saline solution (HBSS) containing 0.05% trypsin and 0.53 mM EDTA (Mediatech). The trypsin was inactivated using RPMI-1640 with 10% FBS, and the cells were washed and collected by centrifugation. The confluent adherent BMSCs showed predominantly fibroblast morphology and were suspended in IMDM, 10% FBS, Pen (100 U/ml), Strep (100 g/ml), and 8 mM L-glutamine.
Preparation of conditioned medium from BMSC cultures
Trypsinized BMSCs from normal donors and MM patients were layered on 24-well polystyrene plates (Falcon; Becton Dickinson, Franklin Lakes, NJ, USA) in a concentration of 1 × 10 5 cells per well. After the BMSCs formed a confluent adherent monolayer, the wells were washed twice with IMDM containing 10% FBS. The MM/EBV transformed B cell lines (RPMI, MM.1S, HS-Sultan) and MM patient cells (MM.1) (2.5 × 10 5 cells/well) were either cultured with BMSCs, or placed in Transwell inserts (Costar, Cambridge, MA, USA), and then cultured with BMSCs. In some experiments, either BMSCs or MM cells were fixed with 1% paraformaldehyde before addition to the cultures in order to determine the source of cytokines. In some cultures, IL-6, VEGF, neutralizing anti-IL-6 antibody, neutralizing anti-VEGF antibody (with appropriate isotype antibody controls), thalidomide, and IMiD1 (CC4047) were used in appropriate final concentrations to discern their effects on cytokine modulation. After incubation at 37°C for 48 h in a 5% CO 2 incubator with 100% humidity (Steri-cult 200 incubator, Forma Scientific, OH, USA), the supernatants were collected after centrifugation (Sorvall RT6000B Refrigerated Centrifuge; DuPont, CT, USA) at 1600 r.p.m. for 5 min. The supernatants were filtered through 0.22 m syringe filters (Costar, Corning, NY, USA), aliquotted in three to four vials, and were frozen at −70°C. All experiments were done in triplicate and the levels depicted are a mean of three experiments for each cell line or patient MM cells.
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Measurements of cytokine levels
VEGF 165 levels in culture supernatants were measured using Enzyme Linked Immunosorbent Assay (ELISA) development reagents (R&D Systems); the levels of IL-6 were measured by DuoSet ELISA development systems (R&D Systems), according to the manufacturer's recommendations. We used quantikine human FGF basic colorimetric sandwich ELISA (R&D Systems) for bFGF quantitation. Briefly, these assays use a sandwich enzyme immunoassay with MoAbs specific for each cytokine precoated on 96-well microtiter plates. Standard control and sample (100 l) are added into wells in triplicate. After an incubation, the wells were washed and an enzyme linked polyclonal antibody specific for each cytokine was added. After washing thoroughly, a substrate solution was added, and color developed in proportion to the amount of cytokine bound. The optical density of each well was determined by a microplate reader at 450 nm. The value of blank was subtracted from the standard control and samples. A standard curve was generated by plotting the mean absorbance of each standard vs the known concentration of cytokine on a log-log scale. Concentrations of various cytokines were reported in picograms/ml. The limit of detection for IL-6 and b-FGF was 10 pg/ml, and for VEGF was 30 pg/ml. Statistical analysis was done using the Microsoft Excel program for mean and standard deviation, and Student's t-test was performed using unpaired t-test in DA stat program. All P values were twotailed; values р0.05 were considered as to be statistically significant.
Results
MM cell lines secrete VEGF
We first measured secretion of VEGF. IL-6 and bFGF in culture supernatants of MM cells/EBV-transformed B cells from MM patients using specific ELISAs. VEGF was secreted by IM-9, HS-Sultan, ARH 77 (EBV transfected B cell lines from MM patients), U266 (Figure 1a 
MM patient and normal donor BMSCs secrete VEGF, IL-6 and bFGF
To assay for paracrine production of these cytokines in the BM, long-term BMSCs were grown as in previous studies. 5, 42 MM-BMSCs and N-BMSCs secreted variable amounts of 
Adhesion of MM cell lines and MM patient cells to N-BMSC and MM-BMSCs induces VEGF and IL-6 secretion
Given our prior studies that adhesion of MM cells to BMSCs can induce NF-B-dependent upregulation in IL-6 secretion, 43 we assayed whether VEGF and bFGF were similarly affected. We observed increased secretion of VEGF and IL-6 when either MM cell lines or patient MM cells were adhered to either N-BMSC or MM-BMSCs (Figure 3a, b and c) . Specifically, VEGF secretion increased by 1.5-to 3.1-fold (P р 0.003), when compared to the sum of VEGF levels from BMSCs and MM cells alone (Figure 3a) . Similarly IL-6 levels increased by 1.9-to 56-fold (P р 0.002) in co-cultures of BMSCs and MM cells, relative to cultures of these cells alone (Figure 3b) . In contrast, bFGF levels decreased (P р 0.09) in 
Source of VEGF and IL-6 secretion triggered by MM to BMSC binding
In order to determine whether the increased secretion of VEGF and IL-6 triggered by MM to BMSC binding was from MM cells and/or BMSCs, either MM cells or BMSCs were fixed with paraformaldehyde prior to adhesion, as in prior studies. 5 As seen in Figure 4a , fixation of BMSCs before HS-Sultan MM cell binding blocked the upregulation of VEGF secretion (P Ͻ 0.001), whereas fixation of HS-Sultan MM cells before adhesion did not alter upregulation of VEGF secretion (P = 0.18), suggesting that BMSCs are the major source for VEGF secretion in this experiment. In the case of IL-6, fixation of tumor cells partially (P Ͻ 0.001), and fixation of BMSCs to a greater extent (P Ͻ 0.001), inhibited adhesion-induced IL-6 secretion (Figure 4g) . None of our cell lines produced IL-6, and it can therefore be concluded that the major source of IL-6 in cocultures is BMSCs (Figure 4h, i, j, k and l) . However,
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Figure 3
Adhesion of MM cells to MM patient and normal donor BMSCs induces VEGF and IL-6 secretion. Levels of (a) VEGF, (b) IL-6, and (c) bFGF (pg/ml) from N-BMSC or MM-BMSCs, MM cell lines and co-cultures of BMSCs and MM cell lines were measured by ELISA.
both BMSCs and MM cells are responsible for increased VEGF secretion in co-cultures (Figure 4b, c, d, e and f) .
In order to determine whether MM cell to BMSC contact is required for upregulation of VEGF and IL-6 secretion, MM cells were placed in Transwell inserts to allow diffusion of humoral factors, but preclude MM cell to BMSC contact. We have previously utilized this system to demonstrate that MM cells secrete TGF-␤ which upregulates IL-6 secretion from BMSCs. 42 When MM.1S cells in Transwell insert chambers were placed in proximity to BMSCs, the induction of VEGF was similar to that noted when MM.1S cells were adhered to BMSCs (P = 0.177) (Figure 5a ), suggesting the importance of a humoral factor/s in these co-cultures. IL-6 secretion was also comparable (P = 0.44) in cultures where MM.1S cells were placed in Transwell insert chambers compared to cultures where MM.1S cells were allowed to adhere to BMSCs (Figure  5f ), suggesting that humoral factor/s may be involved leading to enhanced secretion. These data are consistent with our previous study delineating the role of TGF␤ secreted by MM cells in triggering IL-6 secretion in BMSCs. 42 Similar trends in VEGF (Figure 5b Source of VEGF and IL-6 secretion triggered by MM cell to BMSC binding. Levels of VEGF and IL-6 from MM BMSCs; MM cell lines; co-cultures of MM cells and BMSC; co-cultures of BMSCs and MM cells (fixed by 1% paraformaldehyde); and co-cultures of MM cells and BMSCs (fixed by 1% paraformaldehyde; were measured by ELISA. Panels a, b, c, d, e and f show VEGF secretion and panels g, h, i, j, k and l show IL-6 secretion in experiments using HSS, MM.1S, RPMI, U266, MM1 and MM2 cells. IL-6 was secreted exclusively by BMSCs in these co-cultures whereas VEGF levels were contributed both by BMSCs and MM cells.
Exogenous recombinant VEGF 165 increases IL-6 secretion by BMSCs
Having shown increased VEGF and IL-6 secretion triggered by MM cell binding to BMSCs, we next explored the interplay between VEGF and IL-6 in the BM millieu. BMSCs and MM cells were first stimulated by recombinant VEGF 165 (100 ng/ml), and the secretion of IL-6 was measured by ELISA. As can be seen in Figure 6a , IL-6 secretion in BMSCs increased markedly (158-fold, P Ͻ 0.001) in response to recombinant VEGF 165 stimulation. In contrast, no IL-6 secretion was detected from MM cell lines or patient MM cells after recombinant VEGF 165 stimulation (data not shown). Importantly, goat anti-human VEGF 165 neutralizing polyclonal antibody (1 g/ml) reduced IL-6 secretion by 27% in BMSC cultures (P = 0.002) (Figure 6c ) and by 50% in cultures of MM cells adherent to BMSCs (P Ͻ 0.001) (Figure 6e ). These data demonstrate the role of VEGF secreted by BMSCs and MM cells in triggering IL-6 secretion from BMSCs. Figure 6g also shows a significant decrease in IL-6 secretion (P = 0.001) in co-culture of MM2 cells and BMSCs after addition of anti-human VEGF 165 polyclonal antibody. 
Exogenous recombinant IL-6 increases VEGF secretion by BMSCs and MM cells
BMSCs and MM cells were next stimulated by recombinant IL-6 (10 ng/ml), and the secretion of VEGF was measured by ELISA. As can be seen in Figure 6b , recombinant IL-6 increased VEGF secretion from BMSCs (2.5-fold, P Ͻ 0.001). In addition, HS-Sultan cells stimulated with recombinant IL-6 also upregulated VEGF secretion (1.5-fold, data not shown). However, stimulation of RPMI8226, MM.1S, U266, MM1 and MM2 cells by IL-6 did not increase VEGF secretion. Figure 6d shows no significant change in VEGF secretion by BMSCs alone upon addition of anti-human IL-6 (10 g/ml) MoAb (P = 0.06). Importantly, anti-human IL-6 MoAb reduced VEGF Leukemia levels by 16.8% (P = 0.02) in cultures of HS Sultan cells adhered to BMSCs (Figure 6f ) and by 19% (P = 0.004) in cultures of MM2 cells adhered to BMSCs (Figure 6h ). These data demonstrate the role of IL-6 secreted from BMSCs in triggering VEGF secretion in both MM cells and BMSCs.
Thalidomide and immunomodulatory drug (IMiD1-CC4047) reduce IL-6, and VEGF secretion in cocultures of MM cells and BMSCs
Given the known ability of thalidomide and immunomodulatory drug (IMiD1-CC4047) to modulate cytokines and inhibit angiogenesis, 40 we next examined the effect of thalidomide Immunomodulatory drug (IMiD1-CC4047) (1 M) reduced VEGF (P Ͻ 0.001) and IL-6 (P Ͻ 0.001) secretion in co-cultures of HS Sultan cells and BMSCs (Figure 7a, g ). We detected Leukemia significant decrease in the secretion of VEGF in cultures of BMSCs and MM.1S (Figure 7b 
Thalidomide and immunomodulatory drug (IMiD1-CC4047) reduce VEGF secretion in cultures of MM cells
We also directly examined the effect of these drugs on VEGF secretion in MM cells. Thalidomide reduced VEGF secretion Leukemia significantly in cultures of HS-Sultan (P = 0.02), MM1.S cells (P = 0.03), MM2 cells (P = 0.078) (Figure 8a, b) . Similarly, IMiD1-CC4047 lowered VEGF secretion significantly in HSSultan (P = 0.007), RPMI (P = 0.01), U266 (P = 0.001) and MM2 cells (P Ͻ 0.001) (Figure 8a, b) .
Thalidomide and immunomodulatory drug (IMiD1-CC4047) reduced VEGF and IL-6 secretion in cultures of BMSCs
We also examined the effect of thalidomide and IMID1-CC4047 on secretion of VEGF and IL-6 by myeloma BMSCs alone. Significant reductions in VEGF levels were noted in BMSCs cultures with thalidomide (P = 0.007) and IMID1 (P = 0.004) in experiment 1 (Figure 9a) , and significant reduction in IL-6 secretion was also observed in cultures of BMSCs with IMID1 in experiment 1 (P = 0.05) and in experiment 2 (P = 0.008) (Figure 9b ).
Discussion
Many studies have associated increased angiogenesis with growth and progression of MM. [26] [27] [28] Elevated serum levels of angiogenic cytokines, such as VEGF 44 and bFGF, 45 have been correlated with progression in MM. This prompted us to study these angiogenic cytokines in the context of MM-BMSC interactions, given their pivotal role in the paracrine IL-6-mediated growth and survival of MM cells. 5 We first detected VEGF secretion by all MM cell lines, EBV-transfected B cell lines from MM patients, and patient MM cells, consistent with previous reports. 46, 47 The levels of VEGF in our cultures of MM cell lines, EBV-transfected B cell lines from MM patients, and patient MM cells were well within the range of its biological activity (150-300 pg/ml). 48 We also detected VEGF in supernatants from BMSCs derived from normal donors and from MM patients. It is difficult to say whether BMSCs from MM patients secreted more VEGF than BMSCs from normal donors; the numbers in both groups are small and this observation needs confirmation in studies of large numbers of closely matched normal donors and MM patients. There was no difference in IL-6 secretion between normal and MM patient BMSCs, consistent with our previous report. 5 Importantly, we found up to three-fold increases in VEGF secretion in co-cultures of BMSCs and MM cells, as well as increased IL-6 secretion, as in our previous studies. 5, 43, 49 The source of increased secretion of IL-6 was primarily BMSCs, since fixation of BMSCs prior to MM cell binding abrogated this response. However, increased VEGF secretion was contributed to both by BMSCs and MM cells. The increased VEGF secretion persisted even when MM cells in Transwell insert chambers were juxtaposed to BMSCs, suggesting that VEGF secretion in co-cultures is dependent not only on direct cell to cell contact and adhesion, but also triggered by a diffusible factor. This is analogous to IL-6 secretion, which is induced both by adhesion of MM cells to BMSCs and TGF␤ secreted by MM cells acting on BMSCs. 5, 42 This diffusible factor could be a single cytokine or more likely multiple cytokines -such as IL-6, TNF-␣, TGF-␤, IL-1␤, PDGF, HGF, bFGF, M-CSF, GM-CSF or G-CSF -produced by BMSCs and/or MM cells, which increase the secretion of VEGF and
Figure 9
Thalidomide and immunomodulatory drug (IMiD1-CC4047) reduce VEGF and IL-6 secretion in cultures of BMSCs. Panels and b show the levels of VEGF and IL-6 in BMSCs cultures before and after treatment with THD or IMiD1-CC4047.
IL-6 and thereby enhances growth and survival of MM cells in the BM microenvironment. In this study, we have shown that exogenous IL-6 stimulates VEGF secretion from BMSCs, and conversely, that exogenous VEGF increases IL-6 secretion from BMSCs, consistent with a prior report. 47 Neutralizing antibody to IL-6 or VEGF in co-cultures of MM cells (HSS and MM2) and BMSCs also reduced the secretion of VEGF or IL-6, respectively, further confirming the interplay of these cytokines in MM.
We have shown that VEGF causes significant proliferation of MM.1S cell line and patient MM cells (n = 5) at 100 ng/ml (P Ͻ 0.001) and 1000 ng/ml (P Ͻ 0.001). 50 The biological functions of VEGF are mediated by two VEGF receptors -VEGFR-1 (flt1) 51 and VEGFR-2 (flk-1/KDR). 52 In recent studies, we were able to identify VEGFR-1 in MM.1S and patient MM1 cells by RT-PCR and immunoprecipitation. We also confirmed the biological activity of VEGF in MM.1S cells, as evidenced by specific phosphorylation of tyrosine kinase (Flt-1) receptor after stimulation with VEGF. 50 Our results are consistent with one previous report demonstrating moderate expression of Flt-1 in ARH77 MM cells. 46 These observations indicate that VEGF may play a predominant role in paracrine, and a minor role in autocrine, MM cell growth and are consistent with prior reports. 46, 47 We did not find any increase in proliferation of MM.1S cells in vitro when increasing concentrations of IL-6 (1, 10, 30, 50 ng/ml) were added to VEGF (500 ng/ml) as compared to cultures of MM.1S cells with IL-6 and VEGF separately. 50 In this study, the anti-angiogenic drugs, thalidomide and IMiD1 (CC 4047), reduced VEGF and IL-6 secretion in cocultures of BMSCs and MM cells, highlighting the importance of studying MM cells within the BM millieu. These drugs also caused reduction of VEGF secretion in MM cell lines, and both VEGF and IL-6 secretion in BMSCs alone. Thalidomide was more effective in reducing VEGF and IL-6 levels in cocultures of BMSCs and MM cells, whereas IMID1 (CC 4047) caused greater reductions in VEGF secretion from MM cells and VEGF and IL-6 secretion from BMSCs. Our prior studies show that thalidomide, even at a concentration of 100 M, does not cause apoptosis or G1 growth arrest in MM cell lines, 53 suggesting that this reduction in VEGF secretion triggered by MM-BMSC binding may represent an important mechanism for its anti-MM activity. The more potent IMiD1-CC4047 (1 M) does act directly to induce G1 growth arrest and apoptosis in HS-Sultan, RPMI, U266 and MM2 cells. 53 Therefore, the observed downregulation in VEGF secretion could be due both to direct MM cell toxicity and to inhibition of VEGF secretion in MM-BMSC cultures.
In co-cultures of BMSCs and MM cells, bFGF levels were low. One explanation of this phenomenon could be binding of bFGF to the heparan sulfate proteoglycan syndecan-1, which is abundantly expressed on MM cell lines. 54 Syndecan-1, which is expressed on MM cells, mediates adhesion of tumor cells to extracellular matrix proteins and inhibits tumor cell invasion in collagen gels. Moreover, the shed form of syndecan-1 has been found to inhibit osteoclast formation, modulate bone disease, and induce apoptosis of MM cells. 55 There is evidence that syndecan-1 acts as a positive regulator of the activity of bFGF. 56 Basic FGF subsequently binds to a high affinity tyrosine kinase bFGF receptor, thereby triggering signal transduction. In our study, bFGF levels were higher in cultures of MM cells in Transwell insert chambers and thereby separated from BMSCs (data not shown). This suggests that the decreased bFGF in cultures of MM cells adherent to BMSCs may be due to binding to syndecan-1 on MM cells and possLeukemia ible subsequent downregulation of secretion of bFGF by BMSCs.
We conclude that angiogenic cytokines such as VEGF and bFGF are secreted by BMSCs, and that VEGF is also secreted by most MM cell lines. VEGF and IL-6 secretion increases significantly in cultures of MM cells adherent to BMSCs, due to enhanced secretion of these cytokines from BMSCs in a predominant paracrine fashion. Importantly, anti-angiogenic drugs such as thalidomide and IMiDs abrogate this adhesionrelated upregulation of both VEGF and IL-6, besides having a direct effect on MM and BMSCs. These studies therefore delineate important novel mechanisms of activity of these drugs against MM and further suggest the clinical utility of novel treatment paradigms targeting not only the tumor cell directly, but also cellular interactions and cytokine secretion in the BM millieu.
